Live Breaking News & Updates on Common Hereditary Cancers Panel
Stay updated with breaking news from Common hereditary cancers panel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cigna Healthcare said it will offer Medicare Advantage plans across 29 states in 2024. The company noted that every market has a $0 premium plan, and most plans feature a $0 copay for primary care. ....
Rocket Pharmaceuticals, Inc. (RCKT) announced the FDA has accepted the Biologics License Application and granted Priority Review for RP-L201, a lentiviral vector-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I. ....
The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests. ....
Friday, the FDA granted de novo approval for Invitae Corporation's NVTA Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect… ....